← Back to Clinical Trials
Recruiting NCT05607732

NCT05607732 Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05607732
Status Recruiting
Phase
Sponsor Northwestern University
Condition Dementia
Study Type INTERVENTIONAL
Enrollment 45,257 participants
Start Date 2024-01-30
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MyCog

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45,257 participants in total. It began in 2024-01-30 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, pragmatic trial testing the effectiveness and fidelity of our NIH Toolbox-derived paradigm to improve early detection and management of cognitive impairment/dementia in primary care settings serving health disparate patient populations.

Eligibility Criteria

Inclusion Criteria: * been seen by an Oak Street healthcare provider affiliated with one of the 24 enrolled practices * had at least one clinic visit (routine or Annual Wellness Visit) during the 3-year study period * not been diagnosed previously with cognitive deficits, impairments or dementias. Exclusion Criteria: * Children, adolescence, and younger adults are excluded as cognitive impairment in these populations is often due to differences other than age-related changes.

Contact & Investigator

Central Contact

Michael S Wolf, PhD MPH

✉ mswolf@northwestern.edu

📞 312-503-5592

Frequently Asked Questions

Who can join the NCT05607732 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05607732 currently recruiting?

Yes, NCT05607732 is actively recruiting participants. Contact the research team at mswolf@northwestern.edu for enrollment information.

Where is the NCT05607732 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT05607732 clinical trial?

NCT05607732 is sponsored by Northwestern University. The trial plans to enroll 45,257 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology